Duke’s long leadership in vaccine research and the Duke Human Vaccine Institute’s (DHVI) dogged 25-year pursuit of answers to HIV put the university and health system in an excellent position to address the sudden, global challenge of the novel RNA coronavirus SARS-Cov-2 when it began to sweep around the world in 2020.
Four members of the DHVI faculty joined with Colin Duckett, the vice dean for basic science in the Medical School, to discuss immunology and vaccines as part of Research Week on Feb. 3. Not surprisingly, much of their discussion focused on COVID-19.